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Abstract 
A systematic method was designed to screen a large population of patients with erythropoietic protoporphyria (EPP) for aberrant 
ferrochelatase RNA with skipped exons. The method utilizes the new junction sequence created by exon skipping as the probe to detect 
such RNA species. In 7 of 17 EPP families, an aberrant ferrochelatase RNA with one exon missing was observed. Two previously 
unreported splicing mutations were also identified in 2 EPP families. One was a G >> T transversion atthe + 1 position of the acceptor 
site of intron 8, causing exon 9 to be skipped uring RNA splicing. Both the patient and her father were found to be heterozygous for this 
mutation. In another family, an A >> G transition at the + 3 position of the donor site of intron 10 was identified, associated with exon 10 
skipping during RNA splicing. Both the patient and her father were heterozygous for this mutation. 
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1. Introduction 
EPP is a form of porphyria associated with decreased 
activity of ferrochelatase, the enzyme catalyzing the inser- 
tion of iron into protoporphyrin. Biochemically, this defect 
results in massive accumulations of protoporphyrin ery- 
throcytes, plasma, and feces. Clinically, the disease is 
typically manifested by the childhood onset of cutaneous 
photosensitivity, and may be complicated by hepatobiliary 
dysfunction. The disease was generally considered to be 
inherited in dominant fashion. We monitor more than 20 
patients, from 19 families with this uncommon syndrome. 
When we initiated our search for molecular defects in this 
relatively large population, 6 mutations were known, half 
being splicing mutations involving exon skipping [ l -5] .  
The ferrochelatase gene contains 11 exons. Given the 
heterogenous nature of the known defects, we predicted 
that additional splicing mutations involving exon skipping 
were likely to be present in our patient population. Such 
mutations may cause different exons to be skipped, or 
more than one mutation may lead to the same exon being 
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skipped. To analyze the molecular defects in a cost-effec- 
tive and labor-saving manner, we started the process in a 
systematic fashion. First, the patients were screened against 
all known mutations [6], then a systematic screening 
method was designed to detect any aberrant RNA species 
with a missing exon. This involves 2 major steps. First, 
ferrochelatase cDNA for every patient was amplified and 
blotted on nylon filters; second, 9 specific oligonucleotide 
probes for detecting all possible aberrant RNA species 
with one exon missing were designed and used to hy- 
bridize sequentially with the cDNA on the filters. We thus 
screened 19 patients from 17 EPP families. In this report, 
we also describe the identification of two novel splicing 
mutations responsible for exon skipping that were revealed 
by this systematic approach. 
2. Materials and methods 
2.1. Systematic screening for  ferrochelatase RNA with 
skipped exons 
Primers 5'-GCG TCT AGA CGG GCC GAG GCT 
GCC CAG GC and 5'-GCG AAG CTT CGG GGT CCA 
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Table 1 
Oligonucleotide probes 
Probe Sequence Detecting Temperature for 
mRNA hybridization 
lacking and washing 
1,3-s CGA TCC GCG AAG CCG AA exon 2 52 ° C 
2,4-s CAG AAG AGT AAG CTG GC exon 3 48 ° C 
3,5-s ATT CAG AAC CCC TCA CA exon 4 46 ° C 
4,6-s CCC CCA ACA CAG GCA GCA G exon 5 50 ° C 
5,7-s CCA CCA CAG TGC TTT GC exon 6 50 ° C 
6,8-s TCA TCC AGG TGG TCA AC exon 7 48 ° C 
7,9-s CCG ATG TCT GTT GGT CC exon 8 50 ° C 
8.10-s CAA TCC AAG TGT GGA GT exon 9 46 ° C 
9,11-s TTTTAGCCAAGGAGGCCCT exon 10 54°C 
CCG GCG GGG G were used to amplify the entire 
ferrochelatase coding region [6,7]. The amplified cDNA 
from each of 19 patients was directly dot-blotted on nylon 
filters without purification (10 /xl per dot). Oligonucleo- 
tide probes were designed and synthesized according to the 
new junction sequences created by exon skipping (Table 
1). For example, oligonucleotide 1,3-s was designed to 
detect he joining sequence that results from exon 2 skip- 
ping, and oligonucleotide 2,4-s, the joining sequence that 
results from exon 3 skipping, etc. Nine such oligonucleo- 
tides are needed to detect all possible aberrant RNA 
species with single exon skipping. The filter was first 
hybridized with one of the nine oligonucleotide probes. 
Then, the probe was stripped off and the filter regenerated 
to hybridize with the next oligonucleotide probe. The 
temperatures for the hybridization and washing procedures 
were decided by the T m of each oligonucleotide [7] and 
were fine-tuned empirically (Table 1). 
2.2. Identification qf  splicing mutations 
Patient #1 is a 30-year-old Caucasian female noted to 
have moderate cutaneous photosensitivity in childhood, 
who has been a member of our study population since age 
12 years. Her erythrocyte protoporphyrin levels were typi- 
cally in the 400-600 /xg/dl range (normal, < 50 /zg/dl)  
and her ferrochelatase activity was 28% of normal. She 
continues to be photosensitive, but has had no difficulty 
with gallstones or hepatic dysfunction. None of her parents 
or two siblings is clinically affected; there is no other 
family history of EPP or photosensitivity. 
Patient #2 is a 29-year-old Caucasian female noted to 
have severe cutaneous photosensitivity in childhood, who 
has been a member of our study population since age 8 
years. Her erythrocyte protoporphyrin levels were typically 
in the 2000-3600 p~g/dl range and her ferrochelatase 
activity was 20% of normal. She continues to be extremely 
photosensitive, and developed cholelithiasis at age 28. One 
of her two siblings also has EPP, but is not available for 
study. Neither parent is clinically affected; there is no 
other known family incidence of EPP. 
Exon 9 plus the flanking region was amplified by 
primers 5'-CTT AGC GAT TCG TCT AT (corresponding 
to the intron 8 sequence near its 3' end) and 5'-GAT GGG 
AAA AAG GCA GA (corresponding to the intron 9 
sequence near its 5' end). Exon 10 plus the flanking region 
was amplified by primers 5'-TTC CTC CCT TTT CTC AT 
(corresponding to the intron 9 sequence near its 3' end) 
and 5'-ACT GGA TGT GTG AAT GCA CCA AGT 
(corresponding to the exon 11 sequence at nucleotide 
position 1148-1171 ). 
3. Results 
When an exon X is missing from an RNA sequence, 
exons X - 1 and X + 1 are joined together, creating a new 
junction sequence that can be used as a marker to detect 
the mis-spliced RNA species with exon X skipped. We 
applied this principle to systematically screen for aberrant 
RNA in our population of patients with EPP. We found 
that 7 of our patient families have an aberrant RNA with 
missing exons (Table 2). Of these. 3 were positive for 
9,1 l-s probing, indicating that exon 10 was skipped. The 
skipping in this case was caused by an A >> T transversion 
at the -3  position of the donor site of intron 10. This 
mutation is also a nonsense mutation; therefore, from the 
mutant allele, one either gets an abe.rrant RNA with exon 
10 skipping or a transcript with a premature stop codon [8]. 
The fourth family was positive for 6,8-s probing, indicat- 
ing that exon 7 was skipped. The skipping was caused by a 
G >> A transition at the + 5 positioa of the donor site of 
intron 7 [9]. The fifth family was positive for 8,10-s 
probing and the sixth one, positive for 9,1 l-s probing; the 
mutations responsible for these two aberrant RNA species 
are discussed in detail below. The seventh family was 
Table 2 
Screening results 
Number of Exon Mutation Location Reference 
patients skipped 
3 I 0 A >> T - 3 position of the donor site of intron 10 [7] 
1 7 G >> A + 5 position of the donor site of intron 7 [9] 
I 9 G >> T + 1 position of the acceptor site of intron 8 this paper 
1 10 G >> A + 3 position of the donor site of intron 10 this paper 
1 4 the donor site of intron 4 under study 
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positive for 3,5-s probing and the molecular defect respon- 
sible is currently under study. 
Patient #1. Screening results indicate that this patient 
has aberrant RNA missing exon 9. When the amplified 
ferrochelatase cDNA was examined on agarose gel, three 
bands were seen (Fig. 1, lane 3): one band of normal size 
and two shorter bands. It was confirmed by sequencing 
that the shortest band, also the most intense one, lacked 
exon 9. The rest of the sequence of this aberrant RNA 
species is the same as that already published [10]. The 
middle band was thought at first to be a cDNA with a 
deletion smaller than exon 9. However, when the middle 
band was isolated and cloned, only two types of clones 
were revealed: either one with an insert of normal size or 
one with a shorter insert lacking exon 9. No clones with 
insert size equal to the middle band were ever found. 
These observations uggested that the middle band is a 
heteroduplex formed between normal size cDNA and 
cDNA lacking exon 9. To prove this, amplified cDNA of 
normal size and the one lacking exon 9 were mixed and 
brought through the same amplification process without 
adding Taq polymerase. As expected, the same three-band 
pattern was observed on the gel (Fig. 1, lane 4). The 
cDNA of normal size has the entire sequence as published 
except for an A >> G substitution at nucleotide 287 result- 
ing in a Gln to Arg substitution [10]. This was considered 
by Lamoril et al. to be due to the microheterogeneity of the 
gene [ 1 ], and was also found in several other EPP patients 
[9,11 ]). The cDNA lacking exon 9, however, has no A >> G 
substitution at this position, indicating that normal size 
cDNA and cDNA lacking exon 9 are derived from differ- 
ent alleles. The apparent preferential homoduplex forma- 
tion of cDNA lacking exon 9 during amplification (Fig. 1, 
lane 3) could result from the presence of more template of 
cDNA lacking exon 9, or more efficient amplification of 
the shorter cDNA (12.4% shorter in length compared with 
normal size), or a combination of both. 
Sequencing the amplified genomic fragment containing 
exon 9 plus the flanking regions revealed a G >> T 
transversion at the + 1 position of the acceptor site of 
intron 8 (i.e., the first nucleotide of exon 9, nucleotide 
913). No other mutations were found in this region. Muta- 
tions occurring at the same position causing the affected 
exon to be skipped have been reported for other genes [12]. 
We concluded that this G >> T transversion is responsible 
for exon 9 skipping. The patient is heterozygous for this 
mutation. Her father was also positive for the same muta- 
tion and was also found to have mRNA lacking exon 9. 
Her mother was negative for this mutation. 
This exon skipping does not occur with 100% effi- 
ciency, since the transcript bearing the G >> T transversion 
was detected by allele-specific oligonucleotide hybridiza- 
tion, but at a low level (the transcript has no A >> G 
substitution at nucleotide 287, and thus must be derived 
from the same allele as that lacking exon 9). The G >> T 
transversion on the transcript causes amino acid substitu- 
tion from Val to Phe at position 305. To assess if this 
substitution affects ferrochelatase activity, the transcript 
was cloned into an expression vector and ferrochelatase 
protein was expressed. The enzymatic activity was com- 
pared to that of a normal control. No decrease in the 
activity was observed (data not shown). Therefore, the 
predominant and deleterious effect of the G >> T transver- 
sion is to cause exon 9 skipping. 
Patient #2. Screening results indicated that this patient 
was positive for exon 10 skipping. However, she was 
negative for A >> T transversion at the - 3 position of the 
donor site of intron 10, (a mutation found in three other 
patient families, that is responsible for the skipping of the 
same exon [8]). Sequencing data confirmed the presence of 
both normal cDNA and cDNA lacking exon 10. To iden- 
tify the mutation responsible for the skipping, exon 10 plus 
its flanking region was amplified and sequenced. On one 
of the alleles, an A >> G transition was found at the + 3 
position of the donor site of intron 10. Mutations at this 
position that cause the preceding exon to be skipped have 
been reported in other genes [12,13]. The patient's father 
was also heterozygous for this mutation and found to have 
ferrochelatase RNA lacking exon 10. He manifested re- 
duced ferrochelatase activity at the same level as that of 
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Fig. 1. Reconstitution experiment of amplified ferrochelatase cDNA of patient #1. Lane 0, DNA marker; lane 1, ferrochelatase cDNA lacking exon 9; lane 
2, ferrochelatase cDNA of normal size; lane 3, amplified ferrochelatase cDNA of Patient #1 and lane 4, reconstituted sample: cDNA of normal size and 
cDNA lacking exon 9 were mixed together and brought hrough the same amplification procedure without adding primers and Taq polymerase. 
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his daughter, but he was clinically unaffected. The patient's 
mother was negative for the mutation and her fer- 
rochelatase activity was normal. It appears that this muta- 
tion is responsible for exon 10 skipping. 
4. Discussion 
Three major factors led us to design a novel systematic 
screening method for identifying aberrant RNA species 
with skipped exons: our relatively large population of EPP 
patients, the many splicing mutations previously identified 
in the ferrochelatase gene and the heterogenous nature of 
the defects. The method is rapid and cost-effective, spe- 
cially when a large number of samples and transcripts with 
many exons are involved. It is readily applicable to other 
genes for detecting RNA species with skipped exons. 
Compared to other methods (DNA staining on a sizing 
gel, cloning and sequencing), this method is specific. It 
reveals, in a single procedure, not only an exon-skipping 
event, but also exactly which exon is missing. Therefore, 
attention can immediately be focused on the specific exon 
region to elucidate the responsible splicing mutations at 
the genomic level. By DNA staining on a sizing gel, a 
shorter-than-normal band may suggest an exon-skipping 
event, but only by sequencing can one determine xactly 
which exon is missing. If the skipped exon is small, sizing 
gel methodology may fail to resolve the difference. 
Our method is also more sensitive. Often, an exon-skip- 
ping event can distort the reading frame, leading to a 
premature stop codon. Transcripts bearing a premature 
stop codon are often very unstable and this makes them 
difficult to detect. Because of the insensitive nature of the 
staining of DNA on a sizing gel, transcripts with low 
abundance may not be detectable. Dot-blotting with ra- 
dioactively-labeled oligonucleotide probes is far more sen- 
sitive. In the case of the ferrochelatase gene, skipping of 
exons 3, 5, 7, 8, 9 or 10 leaves the reading frame intact. 
Skipping exons 2, 4 or 6, however, distorts the reading 
frame. By this method, we were able to identify a tran- 
script with exon 4 skipping, even though it was present in 
low abundance. 
The idea of utilizing the new junction sequence as a 
marker has general applicability to detection of mutations 
at the genomic DNA level. Any sequence insertion, dele- 
tion, inversion or translocation can be detected in this 
fashion, as long as the breakpoint is defined and a new 
junction sequence is created. 
Two new splicing mutations of the ferrochelatase g ne 
are presented in this paper. A portion of the data relating to 
one of them on Patient #2 has been reported by us earlier 
[14]. Sarkany et al. [15] have since described an EPP 
family with the same mutation. In that family, both af- 
fected offspring were compound heterozygotes with fer- 
rochelatase deficiency. Both parents had partial enzyme 
deficiency and were each heterozygous for a distinct muta- 
tion. The maternal one is the same as that of our patient 
#2, i.e., an A >> G transition at the +3 position of the 
donor site of intron 10. The paternal one is a missense 
mutation in exon 10. In our case, both the patient and her 
father are heterozygous for the A >> G transition at the + 3 
position of the donor site of intron 10, both have fer- 
rochelatase mRNA lacking exon 19, and both manifest 
reduced ferrochelatase activities. However, only the patient 
has markedly elevated porphyrin levels, and consequently 
manifests the clinical syndrome of EPP; her father has no 
clinical stigma of EPP, although his porphyrin levels are 
slightly elevated. This is another example of variable 
expression of ferrochelatase deficiency. Similarly, both 
patient #1 and her father have mRNA lacking exon 9 
caused by the G >> T transversion at the +1 position of 
the acceptor site of intron 8, but only the patient has 
elevated porphyrin levels and is clinically affected. The 
implication of this phenomenon was discussed in our 
previous publication [9]. The discordance in clinical and 
biochemical manifestations betweer~ the patient and the 
parent suggests that additional factors are required for the 
full expression of the disease. This discordance has been 
previously noted in families with a case of EPP. Asymp- 
tomatic family members have been f~und to have identical 
mutations and variably reduced levels of ferrochelatase 
activity, but only slightly increased erythrocyte protopor- 
phyrin levels [9,11,15], and several mechanisms have been 
speculated upon. Possible explanations have included the 
notions that the inheritance pattern is complex, requiring 
inheritance of a second genetic abnormality from the os- 
tensibly completely normal parent, or that other exogenous 
or endogenous factors contribute to disease xpression. In 
other forms of porphyria (acute intermittent porphyria, 
variegate porphyria, hereditary coproporphyria, familial 
porphyria cutanea tarda), asymptomatic arriers with 
demonstrably deficient enzyme activities but minimal or 
no biochemical abnormalities are not uncommon; exposure 
to exogenous or endogenous factors ~nay precipitate symp- 
toms in such individuals. There are, however, no exoge- 
nous or endogenous factors currently known to uncover 
latent cases of EPP. We favor the hypothesis that a muta- 
tion in the ferrochelatase gene inhe~:ited from one parent 
sets the stage, but a second mutation (either within the 
ferrochelatase locus or elsewhere) is needed for full ex- 
pression. 
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